M032 (NSC 733972)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for M032 (NSC 733972), covering 2026-01-22 to 2026-01-22. Get the full timeline:
Most recent: Clinical Trial Update: Study of Pembrolizumab and M032 (NSC 733972) [Phase 1, Phase 2]